Musculoskeletal Interventions: A Review on Genicular Artery Embolization

AbstractSymptomatic knee pain is one of the most common joint diseases that affects millions of people worldwide. The treatment for knee pain secondary to osteoarthritis (OA) begins with conservative therapy and progresses to surgical intervention when conservative therapy fails. Genicular artery embolization (GAE) offers an alternative option for patients who are poor surgical candidates. Multiple studies have been conducted worldwide demonstrating the safety and efficacy of GAE in patients with mild to moderate OA. The purpose of this article is to describe the current literature on GAE and highlight the latest findings from a randomized controlled trial comparing GAE versus sham embolization.

Download Full-text

3:27 PM Abstract No. 6 Feasibility, safety and efficacy of genicular artery embolization for relief of knee pain related to osteoarthritis

Journal of Vascular and Interventional Radiology ◽

10.1016/j.jvir.2019.12.026 ◽

2020 ◽

Vol 31 (3) ◽

pp. S7

Author(s):

S. Kumar ◽

S. Chandrashekhara

Keyword(s):

Knee Pain ◽

Artery Embolization ◽

Safety And Efficacy ◽

Genicular Artery

Download Full-text

Zoledronic acid plus methylprednisolone versus zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial

Therapeutic Advances in Musculoskeletal Disease ◽

10.1177/1759720x19880054 ◽

2019 ◽

Vol 11 ◽

pp. 1759720X1988005 ◽

Cited By ~ 3

Author(s):

Guoqi Cai ◽

Laura L Laslett ◽

Dawn Aitken ◽

Flavia Cicuttini ◽

Lyn March ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Zoledronic Acid ◽

Knee Osteoarthritis ◽

Knee Pain ◽

Controlled Trial ◽

Intravenous Methylprednisolone ◽

Randomized Controlled ◽

Symptomatic Knee Osteoarthritis ◽

Symptomatic Knee ◽

And Function

Background: The aim of this study was to compare the efficacy and safety of zoledronic acid (ZA) plus intravenous methylprednisolone (VOLT01) to ZA, and placebo for knee osteoarthritis. Methods: A single-center, double-blind, randomized controlled trial (RCT) was carried out. Adults (aged ⩾50 years) with knee osteoarthritis, significant knee pain [⩾40 mm on a 100 mm visual analog scale (VAS)], and magnetic resonance imaging-detected bone marrow lesion (BML) were randomized to receive a one-off administration of VOLT01, ZA, or placebo. The primary hypothesis was that VOLT01 was superior to ZA in having a lower incidence of acute phase responses (APRs) over 3 days. Secondary hypotheses were that VOLT01 was noninferior to ZA, and both treatments were superior to placebo in decreasing BML size over 6 months and in improving knee pain [Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and VAS] and function (WOMAC) over 3 and 6 months. Results: A total of 117 patients (62.2 ± 8.1 years, 63 women) were enrolled. The incidence of APRs was similar in the VOLT01 (90%) and ZA (87%) groups ( p = 0.74). VOLT01 was superior to ZA in improving knee pain and function after 6 months and noninferior to ZA in reducing BML size. However, BML size change was small in all groups and there were no between-group differences. Compared with placebo, VOLT01 but not ZA improved knee function and showed a trend toward improving knee pain after 6 months. Conclusions: Administering intravenous methylprednisolone with ZA did not reduce APRs or change knee BML size over 6 months, but in contrast to ZA or placebo, it may have a beneficial effect on symptoms in knee osteoarthritis. Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000039785.

Download Full-text